Skip to main content
Top
Published in: Breast Cancer Research 5/2009

Open Access 01-10-2009 | Research article

Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study

Authors: Szu-Min Hsieh, Maxime P Look, Anieta M Sieuwerts, John A Foekens, Kent W Hunter

Published in: Breast Cancer Research | Issue 5/2009

Login to get access

Abstract

Introduction

Previous studies in mouse models and pilot epidemiology studies have demonstrated that inherited polymorphisms are associated with inherited risk of tumor progression and poor outcome in human breast cancer. To extend these studies and gain better understanding of the function of inherited polymorphism in breast cancer progression, a validation prognosis study was performed in a large independent breast cancer patient population.

Methods

The study population consisted of 1863 Dutch patients with operable primary breast cancer from Rotterdam, The Netherlands. Genomic DNA was genotyped for the missense Pro436Leu RRP1B single nucleotide polymorphism (SNP) rs9306160 and the intronic SIPA1 SNP rs2448490 by SNP-specific PCR.

Results

A significant association of variants in RRP1B with metastasis-free survival was observed (P = 0.012), validating the role of RRP1B with inherited metastatic susceptibility. Stratification of patients revealed that association with patients' survival was found to be specifically restricted to estrogen receptor positive, lymph node-negative (ER+/LN-) patients (P = 0.011). The specific association with metastasis-free survival only in ER+/LN- patients was replicated for SIPA1, a second metastasis susceptibility gene known to physically interact with RRP1B (P = 0.006). Combining the genotypes of these two genes resulted in the significant ability to discriminate patients with poor metastasis-free survival (HR: 0.40, 95% CI: 0.24 to 0.68, P = 0.001).

Conclusions

These results validate SIPA1 and RRP1B as metastasis susceptibility genes and suggest that genotyping assays may be a useful supplement to other clinical and molecular indicators of prognosis. The results also suggest that lymphatic and hematogeneous metastases are genetically distinct that may involve different mechanisms. If true, these results suggest that metastatic disease, like primary breast cancer, may be multiple diseases and that stratification of late stage patients may therefore be required to fully understand breast cancer progression and metastasis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR: Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 2001, 61: 8866-8872.PubMed Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR: Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res. 2001, 61: 8866-8872.PubMed
2.
go back to reference Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW: Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998, 77: 640-644. 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8.CrossRefPubMed Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW: Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer. 1998, 77: 640-644. 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8.CrossRefPubMed
3.
go back to reference Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW: Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005, 37: 1055-1062. 10.1038/ng1635.CrossRefPubMedPubMedCentral Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X, Hunter KW: Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet. 2005, 37: 1055-1062. 10.1038/ng1635.CrossRefPubMedPubMedCentral
4.
go back to reference Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, Lukes L, Rowe WL, Zhang J, Ambs S, Lowy DR, Anton-Culver H, Hunter KW: Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics. 2007, 3: e214-10.1371/journal.pgen.0030214.CrossRefPubMedPubMedCentral Crawford NP, Qian X, Ziogas A, Papageorge AG, Boersma BJ, Walker RC, Lukes L, Rowe WL, Zhang J, Ambs S, Lowy DR, Anton-Culver H, Hunter KW: Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genetics. 2007, 3: e214-10.1371/journal.pgen.0030214.CrossRefPubMedPubMedCentral
5.
go back to reference Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW: Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006, 8: R16-10.1186/bcr1389.CrossRefPubMedPubMedCentral Crawford NP, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW: Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res. 2006, 8: R16-10.1186/bcr1389.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P: Concordance of survival in family members with prostate cancer. J Clin Oncol. 2008, 26: 1705-1709. 10.1200/JCO.2007.13.3355.CrossRefPubMed Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P: Concordance of survival in family members with prostate cancer. J Clin Oncol. 2008, 26: 1705-1709. 10.1200/JCO.2007.13.3355.CrossRefPubMed
8.
go back to reference Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P: Survival in breast cancer is familial. Breast Cancer Res Treat. 2008, 110: 177-182. 10.1007/s10549-007-9692-7.CrossRefPubMed Hemminki K, Ji J, Forsti A, Sundquist J, Lenner P: Survival in breast cancer is familial. Breast Cancer Res Treat. 2008, 110: 177-182. 10.1007/s10549-007-9692-7.CrossRefPubMed
9.
go back to reference Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K: Survival in bladder and renal cell cancers is familial. J Am Soc Nephrol. 2008, 19: 985-991. 10.1681/ASN.2007070818.CrossRefPubMedPubMedCentral Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K: Survival in bladder and renal cell cancers is familial. J Am Soc Nephrol. 2008, 19: 985-991. 10.1681/ASN.2007070818.CrossRefPubMedPubMedCentral
10.
go back to reference Lindstrom LS, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K: Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol. 2007, 8: 1001-1006. 10.1016/S1470-2045(07)70282-6.CrossRefPubMed Lindstrom LS, Hall P, Hartman M, Wiklund F, Gronberg H, Czene K: Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol. 2007, 8: 1001-1006. 10.1016/S1470-2045(07)70282-6.CrossRefPubMed
11.
go back to reference Qu S, Long J, Cai Q, Shu XO, Cai H, Gao YT, Zheng W: Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res. 2008, 14: 4787-4793. 10.1158/1078-0432.CCR-08-0083.CrossRefPubMedPubMedCentral Qu S, Long J, Cai Q, Shu XO, Cai H, Gao YT, Zheng W: Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res. 2008, 14: 4787-4793. 10.1158/1078-0432.CCR-08-0083.CrossRefPubMedPubMedCentral
12.
go back to reference Freter RR, Alberta JA, Hwang GY, Wrentmore AL, Stiles CD: Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappaB and a 90-kDa phosphoprotein coactivator. J Biol Chem. 1996, 271: 17417-17424. 10.1074/jbc.271.29.17417.CrossRefPubMed Freter RR, Alberta JA, Hwang GY, Wrentmore AL, Stiles CD: Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappaB and a 90-kDa phosphoprotein coactivator. J Biol Chem. 1996, 271: 17417-17424. 10.1074/jbc.271.29.17417.CrossRefPubMed
13.
go back to reference McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006, 100: 229-235. 10.1007/s10549-006-9242-8.CrossRefPubMed McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM: REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006, 100: 229-235. 10.1007/s10549-006-9242-8.CrossRefPubMed
14.
go back to reference Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JGM: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989, 49: 5823-5828.PubMed Foekens JA, Portengen H, van Putten WL, Peters HA, Krijnen HL, Alexieva-Figusch J, Klijn JGM: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res. 1989, 49: 5823-5828.PubMed
15.
go back to reference Crawford NP, Colliver DW, Funke AA, Young MN, Kelley S, Cobbs GA, Petras RE, Galandiuk S: Characterization of genotype-phenotype relationships and stratification by the CARD15 variant genotype for inflammatory bowel disease susceptibility loci using multiple short tandem repeat genetic markers. Hum Mutat. 2005, 25: 156-166. 10.1002/humu.20129.CrossRefPubMed Crawford NP, Colliver DW, Funke AA, Young MN, Kelley S, Cobbs GA, Petras RE, Galandiuk S: Characterization of genotype-phenotype relationships and stratification by the CARD15 variant genotype for inflammatory bowel disease susceptibility loci using multiple short tandem repeat genetic markers. Hum Mutat. 2005, 25: 156-166. 10.1002/humu.20129.CrossRefPubMed
16.
go back to reference Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, Sherman M, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M: Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer. 2009, 124: 1716-1720. 10.1002/ijc.23919.CrossRefPubMedPubMedCentral Gaudet MM, Hunter K, Pharoah P, Dunning AM, Driver K, Lissowska J, Sherman M, Peplonska B, Brinton LA, Chanock S, Garcia-Closas M: Genetic variation in SIPA1 in relation to breast cancer risk and survival after breast cancer diagnosis. Int J Cancer. 2009, 124: 1716-1720. 10.1002/ijc.23919.CrossRefPubMedPubMedCentral
17.
go back to reference The International HapMap Project. Nature. 2003, 426: 789-796. 10.1038/nature02168. The International HapMap Project. Nature. 2003, 426: 789-796. 10.1038/nature02168.
18.
go back to reference Perou CM, Sorlie T, Eisen MB, Rijn van de M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed Perou CM, Sorlie T, Eisen MB, Rijn van de M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature. 2000, 406: 747-752. 10.1038/35021093.CrossRefPubMed
19.
go back to reference Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360: 790-800. 10.1056/NEJMra0801289.CrossRefPubMed Sotiriou C, Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360: 790-800. 10.1056/NEJMra0801289.CrossRefPubMed
20.
go back to reference Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008, 26: 729-735. 10.1200/JCO.2007.14.3222.CrossRefPubMed Cardoso F, Van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol. 2008, 26: 729-735. 10.1200/JCO.2007.14.3222.CrossRefPubMed
21.
go back to reference Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006, 7: 347-350. 10.3816/CBC.2006.n.051.CrossRefPubMed Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006, 7: 347-350. 10.3816/CBC.2006.n.051.CrossRefPubMed
23.
go back to reference Fidler IJ, Kripke ML: Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet. 2003, 34: 23-10.1038/ng0503-23a.CrossRefPubMed Fidler IJ, Kripke ML: Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet. 2003, 34: 23-10.1038/ng0503-23a.CrossRefPubMed
24.
go back to reference Sherley JL: Metastasis: objections to the same-gene model. Nature. 2002, 419: 560-10.1038/419560a. author reply 560CrossRefPubMed Sherley JL: Metastasis: objections to the same-gene model. Nature. 2002, 419: 560-10.1038/419560a. author reply 560CrossRefPubMed
25.
go back to reference Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, Ozato K, Hunter KW: Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA. 2008, 105: 6380-6385. 10.1073/pnas.0710331105.CrossRefPubMedPubMedCentral Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, Ozato K, Hunter KW: Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA. 2008, 105: 6380-6385. 10.1073/pnas.0710331105.CrossRefPubMedPubMedCentral
26.
go back to reference Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW: The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis. 2008, 25: 357-369. 10.1007/s10585-008-9146-6.CrossRefPubMedPubMedCentral Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW: The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis. 2008, 25: 357-369. 10.1007/s10585-008-9146-6.CrossRefPubMedPubMedCentral
27.
go back to reference Lukes L, Crawford NP, Walker R, Hunter KW: The origins of breast cancer prognostic gene expression profiles. Cancer Res. 2009, 69: 310-318. 10.1158/0008-5472.CAN-08-3520.CrossRefPubMedPubMedCentral Lukes L, Crawford NP, Walker R, Hunter KW: The origins of breast cancer prognostic gene expression profiles. Cancer Res. 2009, 69: 310-318. 10.1158/0008-5472.CAN-08-3520.CrossRefPubMedPubMedCentral
28.
go back to reference Crawford NP, Yang H, Mattaini KR, Hunter KW: The metastasis efficiency modifier Ribosomal RNA Processing 1 Homolog B (RRP1B) is a chromatin-associated factor. J Biol Chem. 2009, 284: 28660-28673. 10.1074/jbc.M109.023457.CrossRefPubMedPubMedCentral Crawford NP, Yang H, Mattaini KR, Hunter KW: The metastasis efficiency modifier Ribosomal RNA Processing 1 Homolog B (RRP1B) is a chromatin-associated factor. J Biol Chem. 2009, 284: 28660-28673. 10.1074/jbc.M109.023457.CrossRefPubMedPubMedCentral
29.
go back to reference Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68: 3108-3114. 10.1158/0008-5472.CAN-07-5644.CrossRefPubMed Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW: Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68: 3108-3114. 10.1158/0008-5472.CAN-07-5644.CrossRefPubMed
30.
go back to reference Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13: 4429-4434. 10.1158/1078-0432.CCR-06-3045.CrossRefPubMed Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007, 13: 4429-4434. 10.1158/1078-0432.CCR-06-3045.CrossRefPubMed
31.
go back to reference Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Begin LR, Brunet JS, Narod SA: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer. 2003, 98: 1569-1577. 10.1002/cncr.11688.CrossRefPubMed Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Begin LR, Brunet JS, Narod SA: Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer. 2003, 98: 1569-1577. 10.1002/cncr.11688.CrossRefPubMed
32.
go back to reference Tsukamoto N, Hattori M, Yang H, Bos JL, Minato N: Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J Biol Chem. 1999, 274: 18463-18469. 10.1074/jbc.274.26.18463.CrossRefPubMed Tsukamoto N, Hattori M, Yang H, Bos JL, Minato N: Rap1 GTPase-activating protein SPA-1 negatively regulates cell adhesion. J Biol Chem. 1999, 274: 18463-18469. 10.1074/jbc.274.26.18463.CrossRefPubMed
Metadata
Title
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study
Authors
Szu-Min Hsieh
Maxime P Look
Anieta M Sieuwerts
John A Foekens
Kent W Hunter
Publication date
01-10-2009
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2009
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2412

Other articles of this Issue 5/2009

Breast Cancer Research 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine